Project Grant R21AG101124
- Federal Grant Award Summary Emory University received a $657,222 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 15, 2026, with completion by January 31, 2031. This research initiative will define pathological roles of novel protein interactions with amyloid in Alzheimer's disease (AD) by testing the Amyloid Scaffold Hypothesis (ASH). The project will deliver three primary research products: (1) quantitative proteomic...
- Federal Project Grant Award Summary Emory University received a $430,375 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded July 1, 2025, with completion expected June 30, 2027. This award funds research investigating membrane trafficking impairments in Fragile X Syndrome (FXS), the most common form of inherited intellectual disability and...
- Federal Project Grant Award Summary Emory University received a $651,466 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective February 15, 2026, through November 30, 2030. The research project investigates the role of promyelocytic leukemia protein (PML) in oxidative stress and Alzheimer's disease (AD) pathogenesis, with focus on understanding how PML regulates microRNA (miRNA) biogenesis through the microprocessor complex—the...
- Federal Grant Award Summary Emory University received a $234,750 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 11, 2026, with a completion date of April 30, 2028. The research project investigates NMDA (N-methyl-D-aspartate) receptor regulation of rapid synaptic scaling and spinal excitability in Fragile X Syndrome, a...
- Federal Grant Award Summary Emory University received a $643,613 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective April 1, 2026, through January 31, 2031. This award supports innovative research to discover glycosylation-based disease processes and identify glyco-biomarkers and therapeutic targets for improving Alzheimer's disease (AD) diagnosis, prognosis, and intervention. The research will utilize an integrated platform...
- Federal Project Grant Award Summary Emory University received a $149,190 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded August 6, 2026, with a completion date of February 28, 2029. The research project, "Neuromelanin Formation and Toxicity in the Locus Coeruleus: The Role of Norepinephrine Metabolism," delivers scientific investigation and research services directed toward understanding the mechanisms underlying...
- Federal Grant Award Summary Emory University received a $149,190 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on July 26, 2026, with a completion date of January 31, 2029. The research project focuses on the functional and biochemical analysis of RNA exosome variants linked to neurological disorders, specifically examining missense...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $805,573 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), with an award date of September 15, 2025, and a completion date of June 30, 2030. This research project investigates the impact of N6-methyladenosine (M6A) RNA modifications in Alzheimer's disease and related tauopathies. The research will characterize how M6A-RNA dysregulation contributes...
- Federal Project Grant Award Summary Emory University received a $147,656 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), with an award date of March 11, 2025 and project completion date of September 29, 2025. The grant supports the development of the first human locus coeruleus (LC) organoid model to advance understanding of Alzheimer's disease (AD) pathology. The research addresses a critical gap in AD knowledge by utilizing...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $493,972 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to support the research project titled "Cell Type-Specific Epitranscriptomic Regulation in the Brain in Aging and Alzheimer's Disease." The award, effective January 1, 2026 through December 31, 2030, funds basic biomedical research investigating how chemical modifications to...
Emory University received a $430,375 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective May 15, 2026, through April 30, 2028. The research project investigates the role of N6-methyladenosine (M6A), a critical RNA modification in the brain, in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) pathogenesis. FXTAS is a progressive neurodegenerative disorder affecting carriers of CGG premutation expansions in the FMR1 gene, characterized by tremor, gait ataxia, parkinsonism, and cognitive decline. The research aims to elucidate how M6A dysregulation contributes to neurodegeneration and to translate findings into clinically relevant therapeutic strategies. The project delivers scientific research products and knowledge outputs examining the epitranscriptomic landscape—specifically M6A regulatory proteins and methylation patterns—in postmortem FXTAS and control human cortex tissue. Preliminary studies demonstrate significant changes in M6A regulatory mechanisms and provide evidence that genetic disruption of the M6A pathway exacerbates CGG repeat-induced neurotoxicity in disease models. By defining the molecular mechanisms underlying FXTAS pathogenesis through epitranscriptomic analysis, this research contributes to understanding shared mechanisms across neurodegenerative diseases and supports the National Institute on Aging's mission to prevent and treat age-related neurological conditions.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $430.4k | 5/8/26 |